BCL2 and prostate cancer: Bcl-2 and AKT1 interaction was sustained by evidence in curated pathways from BioCarta, as of September 2018 (https://cgap.nci.nih.gov/Pathways/BioCarta_Pathways (accessed on 25 July 2021)), or Kyoto Encyclopedia of Genes and Genomes (KEGG), as of June 2018, involved in platinum drug resistance, colorectal cancer, small cell lung cancer, and prostate cancer [47,48,49].